- Leukotriene inhibitors, a class of anti-inflammatory medications, are becoming increasingly vital in the management of chronic respiratory conditions such as asthma, allergic rhinitis, and COPD. These drugs are favoured for their oral administration, steroid-sparing effects, and targeted mechanism of action, offering enhanced patient compliance and long-term control of symptoms
- The escalating demand for leukotriene inhibitors is primarily fueled by the rising prevalence of asthma and allergic diseases globally, growing awareness of long-acting maintenance therapies, and increased preference for non-steroidal treatment options among patients and healthcare providers
- North America dominated the leukotriene inhibitors market with the largest revenue share of 41.7% in 2024, attributed to early diagnosis rates, widespread availability of branded drugs such as montelukast and zafirlukast, and supportive reimbursement frameworks. The U.S. leads the region’s growth, bolstered by robust healthcare infrastructure, increasing patient awareness, and extensive use of maintenance therapies in both pediatric and adult populations
- Asia-Pacific is expected to be the fastest-growing region in the leukotriene inhibitors market during the forecast period, projected to register a CAGR of 10.8%. This growth is driven by rapid urbanization, rising pollution levels contributing to respiratory ailments, and increased healthcare access in emerging economies such as India and China
- Montelukast segment dominated the leukotriene inhibitors market with a market share of 67.3% in 2024, owing to its wide clinical adoption, availability in generic forms, and favorable safety profile. Its use in both monotherapy and combination therapy regimens further supports its strong market position
